CN104395319B - 用作ampk的活化剂的噻吩并吡啶酮衍生物 - Google Patents

用作ampk的活化剂的噻吩并吡啶酮衍生物 Download PDF

Info

Publication number
CN104395319B
CN104395319B CN201380034638.0A CN201380034638A CN104395319B CN 104395319 B CN104395319 B CN 104395319B CN 201380034638 A CN201380034638 A CN 201380034638A CN 104395319 B CN104395319 B CN 104395319B
Authority
CN
China
Prior art keywords
chloro
thieno
pyridin
hydroxy
ampk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380034638.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104395319A (zh
Inventor
D·克拉沃
S·阿拉库-博泽克
S·博尔兹
F·勒皮弗尔
L·法韦里尔
J-D·迪朗
C·卡龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Priority to CN201710493350.XA priority Critical patent/CN107266467A/zh
Publication of CN104395319A publication Critical patent/CN104395319A/zh
Application granted granted Critical
Publication of CN104395319B publication Critical patent/CN104395319B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380034638.0A 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物 Active CN104395319B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710493350.XA CN107266467A (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305775.4A EP2679591A1 (en) 2012-06-29 2012-06-29 Thienopyridone derivatives useful as activators of AMPK
EP12305775.4 2012-06-29
PCT/EP2013/063741 WO2014001554A1 (en) 2012-06-29 2013-06-28 Thienopyridone derivatives useful as activators of ampk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710493350.XA Division CN107266467A (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Publications (2)

Publication Number Publication Date
CN104395319A CN104395319A (zh) 2015-03-04
CN104395319B true CN104395319B (zh) 2017-10-27

Family

ID=48703549

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380034638.0A Active CN104395319B (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物
CN201710493350.XA Pending CN107266467A (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710493350.XA Pending CN107266467A (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Country Status (26)

Country Link
US (1) US9284329B2 (https=)
EP (2) EP2679591A1 (https=)
JP (1) JP5972460B2 (https=)
KR (1) KR101704448B1 (https=)
CN (2) CN104395319B (https=)
AU (1) AU2013283239B2 (https=)
BR (1) BR112014032526B1 (https=)
CA (1) CA2876789C (https=)
CY (1) CY1118213T1 (https=)
DK (1) DK2867240T3 (https=)
EA (1) EA026300B1 (https=)
ES (1) ES2603737T3 (https=)
HR (1) HRP20161482T1 (https=)
HU (1) HUE030946T2 (https=)
IL (1) IL236221A (https=)
IN (1) IN2014MN02661A (https=)
LT (1) LT2867240T (https=)
ME (1) ME02537B (https=)
MX (1) MX359221B (https=)
PL (1) PL2867240T3 (https=)
PT (1) PT2867240T (https=)
RS (1) RS55308B1 (https=)
SI (1) SI2867240T1 (https=)
SM (1) SMT201600418B (https=)
WO (1) WO2014001554A1 (https=)
ZA (1) ZA201500593B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105078992B (zh) * 2014-05-23 2017-11-21 资元堂生物科技股份有限公司 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104910130A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和氨基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104910129A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 含六甲基苯环和卤代苯结构的黄原酸酯类化合物、其制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN105541715B (zh) * 2016-02-02 2019-04-09 浙江工业大学 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用
KR101925020B1 (ko) 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
CA3087830A1 (en) * 2018-02-08 2019-08-15 Enyo Pharma Non-fused thiophene derivatives and their uses
CN108516972A (zh) * 2018-05-30 2018-09-11 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
MX2021005772A (es) * 2018-11-16 2021-10-13 Poxel Sal de monohidrato potasico de un derivado de tienopiridona y su proceso de preparacion.
US20220184172A1 (en) * 2019-04-19 2022-06-16 The Regents Of The University Of California Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
WO2021037702A1 (en) 2019-08-28 2021-03-04 Poxel Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
EP4065104A1 (en) * 2019-11-27 2022-10-05 Société des Produits Nestlé S.A. Dibenzopyran ampk activator compounds, compositions, methods and uses thereof
AU2021244824A1 (en) 2020-03-26 2022-10-27 Poxel Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
WO2021198284A1 (en) 2020-03-30 2021-10-07 Poxel Use of a thienopyridone derivative in the treatment of cardiovascular diseases
US20230149370A1 (en) 2020-03-30 2023-05-18 Poxel Use of a thienopyridone derivative in the treatment of diabetic nephropathy
BR112022019403A2 (pt) * 2020-04-02 2022-12-06 Poxel Uso de um derivado de tienopiridona no tratamento de doença renal policística autossômica dominante (drpad)
WO2021204755A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
WO2021204751A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133843A (zh) * 1994-12-15 1996-10-23 默克专利股份有限公司 噻吩并吡啶酮
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
CN101061123A (zh) * 2004-10-07 2007-10-24 Epix特拉华公司 噻吩并吡啶酮化合物及治疗方法
CN101232883A (zh) * 2005-08-18 2008-07-30 默克专利有限公司 作为ampk激活剂的噻吩并吡啶酮衍生物的用途及包含它们的药物组合物
CN101998853A (zh) * 2008-04-11 2011-03-30 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)激活剂的噻吩并吡啶酮衍生物
CN102015676A (zh) * 2008-05-05 2011-04-13 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)活化剂的噻吩并吡啶酮衍生物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133843A (zh) * 1994-12-15 1996-10-23 默克专利股份有限公司 噻吩并吡啶酮
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
CN101061123A (zh) * 2004-10-07 2007-10-24 Epix特拉华公司 噻吩并吡啶酮化合物及治疗方法
CN101232883A (zh) * 2005-08-18 2008-07-30 默克专利有限公司 作为ampk激活剂的噻吩并吡啶酮衍生物的用途及包含它们的药物组合物
CN101998853A (zh) * 2008-04-11 2011-03-30 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)激活剂的噻吩并吡啶酮衍生物
CN102015676A (zh) * 2008-05-05 2011-04-13 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)活化剂的噻吩并吡啶酮衍生物

Also Published As

Publication number Publication date
CA2876789A1 (en) 2014-01-03
JP5972460B2 (ja) 2016-08-17
AU2013283239A1 (en) 2015-01-22
BR112014032526B1 (pt) 2022-11-01
EP2867240B1 (en) 2016-09-14
RS55308B1 (sr) 2017-03-31
KR101704448B1 (ko) 2017-02-08
US20150166566A1 (en) 2015-06-18
EP2679591A1 (en) 2014-01-01
PT2867240T (pt) 2016-11-24
US9284329B2 (en) 2016-03-15
WO2014001554A1 (en) 2014-01-03
CN104395319A (zh) 2015-03-04
HRP20161482T1 (hr) 2016-12-30
HUE030946T2 (en) 2017-06-28
IL236221A (en) 2017-12-31
CN107266467A (zh) 2017-10-20
KR20150033709A (ko) 2015-04-01
ES2603737T3 (es) 2017-03-01
CY1118213T1 (el) 2017-06-28
CA2876789C (en) 2017-01-31
PL2867240T3 (pl) 2017-02-28
EP2867240A1 (en) 2015-05-06
MX2014016107A (es) 2015-11-16
EA201500064A1 (ru) 2015-08-31
DK2867240T3 (en) 2016-12-05
EA026300B1 (ru) 2017-03-31
IN2014MN02661A (https=) 2015-08-28
ME02537B (me) 2017-02-20
JP2015521651A (ja) 2015-07-30
IL236221A0 (en) 2015-02-01
MX359221B (es) 2018-09-18
AU2013283239B2 (en) 2016-01-28
ZA201500593B (en) 2016-01-27
BR112014032526A2 (pt) 2017-06-27
LT2867240T (lt) 2016-12-27
SI2867240T1 (sl) 2017-01-31
SMT201600418B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
CN104395319B (zh) 用作ampk的活化剂的噻吩并吡啶酮衍生物
JP5559894B2 (ja) Ａｍｐｋのチエノ［２，３−ｂ］ピリジンジオンアクチベーターおよびその治療的使用
CN102149384B (zh) 作为ep4受体拮抗剂的杂环酰胺衍生物
CN101959404B (zh) 单磷酸腺苷活化蛋白激酶调节剂
CN103517896B (zh) 喹啉酮衍生物
EA020773B1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
US20120172333A1 (en) Pyrrolo-pyridine derivatives as activators of ampk
CN106573934A (zh) 瞬时受体电位a1离子通道的抑制
CN103313707A (zh) 二苯基-胺衍生物的用途、合成方法及药物组合物
CN118666843A (zh) 喹诺里西啶类组蛋白去乙酰化酶抑制剂及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant